Evidence map›Paper›PMID 33123933›Full record

ArticleCytotechnology2020

Production of lentiviral vectors in suspension cells using low proportion of supercoiled circular plasmid DNA.

Xin-An Lu, Ting He, Zhihai Han, Yanping Ding, Liang Zhao, Guanghua Liu, Floris De Smet, Xiaojun Huang, Danqing Chen, Feifei Qi and 1 more

Abstract read
In one paragraph

Article in Cytotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xin-An LuImmunochina Pharmaceuticals Co., Ltd, 100089, Beijing, China.
Ting HeImmunochina Pharmaceuticals Co., Ltd, 100089, Beijing, China.
Zhihai HanDepartment of Pulmonary and Critical Care Medicine, The Sixth Medical Center of PLA General Hospital, 100048, Beijing, China.
Yanping DingImmunochina Pharmaceuticals Co., Ltd, 100089, Beijing, China.
Liang ZhaoImmunochina Pharmaceuticals Co., Ltd, 100089, Beijing, China.
Guanghua LiuImmunochina Pharmaceuticals Co., Ltd, 100089, Beijing, China.
Floris De SmetSartorius Stedim North America Inc., 565 Johnson Avenue, Bohemia, New York, 11716, USA.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, 100044, Beijing, China.
Danqing ChenImmunochina Pharmaceuticals Co., Ltd, 100089, Beijing, China.
Feifei QiImmunochina Pharmaceuticals Co., Ltd, 100089, Beijing, China. qifeifei@immunochina.com.
Xiangyu ZhaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, 100044, Beijing, China. zhao_xy@bjmu.edu.cn.ORCID https://orcid.org/0000-0002-8139-1773

Funding

Beijing Municipal Science & Technology Commission Z171100001017098Beijing Municipal Science & Technology Commission Z181100002218040Beijing Municipal Science & Technology Commission Z181100006218036Beijing Municipal Science & Technology Commission Z191100001119097Clinical Medicine Plus X-Young Scholars Project of Peking University PKU2020LCXQ015Peking University People's Hospital Research and Development Funds RDX2019-14the Peking University Clinical Scientist Program BMU2019LCKXJ003the Scientific Research Foundation for Capital Medicine Development 2018-2-4084Zhongguancun Science Park Management Committee 201805028-1
6 · The paper itself

Abstract

The supercoiled circular (SC) topology form of plasmid DNA has been regarded to be advantageous over open circular or linearized analogue in transfection and expression efficiency, and therefore are largely demanded in the biopharmaceutical manufacturing. However, production of high-purity SC plasmid DNA would result in high manufacturing cost. The effect of SC proportion in plasmid DNA on the quality of packaged lentiviral vectors has never been reported. In this study, we established an efficient system for production of high-titer lentiviral vectors using suspension HEK293SF cells in serum-free media, and the lentiviral titer was not associated with the proportion of SC plasmid DNA. Plasmids DNA with different proportion of SC, open-circular, and linearized forms were prepared using the thermal denaturation method, and were transfected to adherent HEK293T or suspension HEK293SF cells for packaging of lentiviral vectors. The titer of lentiviral vectors from HEK293T cells, but not from HEK293SF cells, was significantly impaired when the proportion of SC plasmid DNA decreased from 60-80% to 30-40%. Further decrease of SC plasmid proportion to 3% led to a dramatic reduction of lentiviral titer no matter the packaging cell line was. However, lentiviral vectors from HEK293SF cells still showed a high titer even when the proportion of SC plasmid DNA was 3%. This study demonstrated that extremely high proportion of SC plasmid DNA was not required for packaging of high-titer lentiviral vector in HEK293SF cells, at least under our manufacturing process.

Indexed as

Lentiviral vectorProportionSupercoiled circular plasmid DNASuspension cell cultureTiter

Identifiers

PMID33123933
PMCPMC7695760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.